Voriconazole is a new-generation triazole antifungal agent with potent activity against a wide range of clinically significant pathogens, including Aspergillus and Candida, as well as some less common fungal pathogens. Since its approval in 2002, voriconazole has changed the approach to the management of invasive fungal diseases. The Infectious Diseases Society of America guidelines now recommend voriconazole as the first-line drug for the treatment of invasive aspergillosis and as an alternative drug for the treatment of candidemia.
Betadex sulfobutyl ether soudium as key excipient on voriconazole has increase water solubility
and improve bioavailability. It derivative by beta cyclodextrin with 1,4-butane sulfonate, is an anionic, highly water-soluble bettaclodextrin derivative. Betadex sulfobutyl ether soudium inclusion ruasidone hydrochloride can be well combined with drug molecules to form a non-covalent complex, to improve the stability of drugs, water soluble, safety, reduce nephrotoxicity, moderate drug hemolysis, control drug release rate, cover up bad smell, etc., widely used in injection, oral medicine, nasal medication, eye medication, external drug and inhalation, etc., provides a beneficial protection environment, is a very broad application prospect of new pharmaceutical materials.
